Efficacy, immunogenicity and safety of the AS04-HPV-16/18 vaccine in Chinese women aged 18-25 years: End-of-study results from a phase II/III, randomised, controlled trial.
Cancer Med
; 8(14): 6195-6211, 2019 10.
Article
in En
| MEDLINE
| ID: mdl-31305011
Key words
Full text:
1
Collection:
01-internacional
Database:
MEDLINE
Main subject:
Papillomavirus Infections
/
Human papillomavirus 16
/
Human papillomavirus 18
/
Papillomavirus Vaccines
/
Immunogenicity, Vaccine
Type of study:
Clinical_trials
/
Guideline
Limits:
Adolescent
/
Adult
/
Female
/
Humans
Country/Region as subject:
Asia
Language:
En
Journal:
Cancer Med
Year:
2019
Document type:
Article
Affiliation country:
Country of publication: